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Abstract
Background: To evaluate and compare the utility of 18F-fluorocholine (18F-CH) PET/CT versus 3-Tesla multiparametric
MRI (mpMRI) without endorectal coil to detect tumor recurrences in patients with biochemical relapse following
radical prostatectomy (RP). Secondarily, to identify possible prognostic variables associated with mpMRI and 18F-CH
PET/CT findings.
Methods: Retrospective study of 38 patients who developed biochemical recurrence after RP between the years 2011
and 2015 at our institution. PET/CT and mpMRI were both performed within 30 days of each other in all patients. The
PET/CT was reviewed by a nuclear medicine specialist while the mpMRI was assessed by a radiologist, both of whom
were blinded to outcomes.
Results: The median prostate-specific antigen (PSA) value pre-MRI/PET-CT was 0.9 ng/mL (interquartile range 0.4–2.
2 ng/mL). There were no differences in the detection rate between 18F-CH PET/CT and mpMRI for local recurrence
(LR), lymph node recurrence (LNR) and bone metastases (BM). Separately, mpMRI and 18F-CH PET/CT were positive for
recurrence in 55.2% and 52.6% of cases, respectively, and in 65.7% of cases when findings from both modalities were
considered together. The detection of LR was better with combined mpMRI and choline PET/CT versus choline PET/CT
alone (34.2% vs 18.4%, p = 0.04). Salvage treatment was modified in 22 patients (57.8%) based on the imaging findings.
PSA values on the day of biochemical failure were significantly associated with mpMRI positivity (adjusted odds ratio
(OR): 30.9; 95% confidence interval (CI): 1.5–635.8). Gleason score > 7 was significantly associated with PET/CT positivity
(OR: 13.9; 95% CI: 1.5–125.6). A significant association was found between PSA doubling time (PSADT) (OR: 1.3; 95%
CI: 1.0–1.7), T stage (OR: 21.1; 95% CI: 1.6–272.1), and LR.
Conclusions: Multiparametric MRI and 18F-CH PET/CT yield similar detection rates for LR, LNR and pelvic BM. The
combination of both imaging techniques provides a better LR detection versus choline PET/CT alone. The initially
planned salvage treatment was modified in 57.8% of patients due to imaging findings. In addition to PSA values,
Gleason score, T stage, and PSADT may provide valuable data to identify those patients that are most likely to benefit
from undergoing both imaging procedures.
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Background
After radical prostatectomy (RP), 20–50% of patients with
prostate cancer (PCa) will develop a tumor recurrence
within ten years [1]. In patients with recurrent disease, ac-
curate identification of the site of recurrence is crucial be-
cause the type of salvage treatment administered depends
on whether the patient presents pelvic recurrence: local re-
currence (LR) with or without pelvic lymph node
recurrence (LNR) and/or bone metastases (BM), or extra-
pelvic distant metastases [2]. Currently, multiparametric
magnetic resonance imaging (mpMRI) and 11C or 18F-
choline (18F-CH) PET/CT are considered the diagnostic im-
aging tests of choice in this patient population [2]. However,
in recent years prostate-specific membrane antigen (PSMA)-
ligand imaging has shown promising results in detecting re-
currences after RP, and for this reason use of this approach
has become increasingly common [for a Review, see 3].
Multiparametric MRI has proven useful in the detection
of LR in the prostate gland, even in patients with low
prostate-specific antigen (PSA) levels (<0.5 ng/mL) [4],
although few studies have assessed the value of mpMRI to
LNR or pelvic bone BM [2, 5]. By contrast, 18F-CH
PET/CT has proven effective in detecting LNR and
BM after RP, primarily in patients with PSA >1 ng/mL or
with PSA doubling time (PSADT) < 6 months [6]. The
utility of 18F-CH PET/CT to detect LR has received only
scant attention [1, 7].
Panebianco et al. compared mpMRI with endorectal
coil, dynamic contrast enhanced (DCE), and spectros-
copy to 18F-CH PET/CT [7], finding that mpMRI was
more reliable at detecting LR. Another study recently
compared mpMRI with endorectal coil to 11C-choline
PET/CT to detect pelvic recurrences [8], finding that
mpMRI was more accurate in detecting LR whereas
11C-PET/CT yielded better results in detecting LNR.
Both methods presented similar detection rates for bone
metastases. Other studies evaluating the role of PET/CT
and mpMRI in PCa staging have found that the sen-
sitivity of mpMRI to detect nodal metastases is similar
to, or slightly lower than, that of choline PET/CT [9–11].
A recent meta-analysis found that mpMRI had a higher
sensitivity and a lower specificity than choline PET/CT in
the diagnosis of BM [12]. To our knowledge, no studies
have been conducted to date to directly compare 3T-
mpMRI without endorectal coil with diffusion weighted
imaging (DWI) and DCE to 18F-CH PET/CT in the de-
tection of pelvic recurrences after RP.
Given this context, the aim of the present study was to
compare 18F-CH PET/CT to 3T mpMRI with a phased-
array torso coil to determine their relative capabilities to
detect pelvic LR, LNR, and BM after RP and to assess
their impact on salvage therapy. Secondarily, we ana-
lyzed numerous clinical variables to determine potential
predictors of positive findings on the imaging studies.
Methods
Study population
This was a retrospective, observational study of a cohort of
59 patients diagnosed with PCa who underwent 18F-FCH
PET/CT at the Nuclear Medicine Department of the Hos-
pital Universitario Quiron in Madrid between November
2011 and July 2015. Of these 59 patients, 21 were excluded
from the study due to the following: staging 18F-CH PET/
CT performed prior to the initial treatment (n = 5); biochem-
ical failure after radical radiotherapy (n= 10); missing
mpMRI (n= 3); lost to follow-up (n= 3). Therefore, all pa-
tients who presented a biochemical recurrence (defined as
two consecutive elevations of PSA >0.2 ng/mL) after RP and
also underwent mpMRI without endorectal coil and 18F-CH
PET/CT within a maximum of 30 days of each other were
included in the study (n= 38). The PSA values assessed prior
to mpMRI and PET/CT imaging were statistically not sig-
nificantly different. Patients who received salvage RT and/or
androgen-deprivation therapy (ADT) after RP (n= 11) were
also included. The study was approved by our institution’s
ethics committee.
Multiparametric magnetic resonance imaging protocol
The mpMRI protocol has been described in detail else-
where [3, 13, 14]. Briefly, a 3T MRI was used (Signa
HDxt 3.0 T G.E. Healthcare; Milwaukee, WI, USA) with
a gradient strength of 33 mT/m and a gradient slew rate
of 120 T/m/s. An 8-channel surface coil was used (Torso
phased array). Morphological imaging included T1- and
T2-weighted sequences and functional studies included
DWI and DCE imaging. The apparent diffusion coeffi-
cient (ADC) map was calculated while using DWI and
b-values of 0 and 1000 s/mm2 were used. DCE imaging
was performed with gadolinium contrast. For DCE, a
qualitative review was performed and uptake patterns of
relapse-suspected lesions were classified as follows: type
1 curve (slow and progressive uptake), type 2 curve
(initial uptake followed by a plateau), or type 3 curve
(intense initial uptake followed by washout).
18F-choline PET/CT protocol
Patient preparation for PET-CT consisted of 4–6 h of
fasting. All patients received an intravenous injection of
18F-fluoromethylcholine (4 MBq/kg) supplied by the
Instituto Tecnologico PET (ITP) in Madrid. Whole body
scan was started 60–90 min after injection of 18F-CH.
Early dynamic images were not obtained. We just ac-
quired late imaging. The whole-body acquisition was
performed in the three dimensional mode, using 2 min
per bed position from the base of the skull to the mid-
thigh (six or seven bed positions). Images were recon-
structed with a standard reconstruction ordered-subset
expectation maximization iterative algorithm (two itera-
tive steps) and reformatted into transverse, coronal and
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sagittal views. Diagnostic CT protocols (oral and intra-
venous contrasts) were applied. Furosemide was not
used in this study. PET-CT scanning was performed
using a Biograph 6 True Point HD LSO integrated de-
vice (Siemens Healthcare Molecular Imaging; Knoxville,
Tennessee, USA) with an intrinsic axial resolution of
4.1 mm FWHM and iterative reconstruction. The CT
scan (130–136 keV; 60–90 mAs) was taken in direct
proportion to the patient’s weight, followed by a PET
scan (performed in the same parameter range) for 3 min
per bed (approximately 6–7 min). The PET data were
processed with iterative reconstruction and converted
into PET images (based on CT) with and without at-
tenuation correction. Acquired images were examined
on an LCD monitor as both attenuation-corrected and
uncorrected multiplanar PET, CT, and PET/CT fusion
cross-sections (maximum intensity projection =MIP),
using the eSOFT software (Siemens, USA).
Image analysis
A radiologist and a nuclear physician, both experts in
uro-oncology, retrospectively reviewed the mpMRI and
18F-CH PET/CT images. These specialists performed
the analysis independently of each other and both were
blinded to outcomes. Radiological findings were scored
from 1 to 3, as follows: a score of 1 indicated a negative
finding (absence of recurrence), 2 was considered inde-
terminate, and 3 indicated positive findings (presence of
recurrence). This same scoring approach was used to as-
sess LR and bone and nodal metastases. All lesions with
a score of 1 or 2 were considered negative for the pur-
poses of the present study. The image analyses were per-
formed as follows:
mpMRI
The diffusion sequence and the dynamic contrast-enhanced
study were processed in a workstation (Advantage
Workstation 4.3; GE Healthcare, Milwaukee, WI, USA).
T2 and DWI sequences included the whole pelvis and iliac
crests. DCE imaging was performed only in the prostate
bed. LR was measured using the T2, DWI and DCE se-
quences while LNR and BM were assessed with T2 and
DWI sequences. There is no validated scoring system to
define a recurrence after RP on mpMRI [5]; consequently,
we used the following mpMRI criteria for LR: presence of
a soft tissue nodule on T2-weighted images in or around
the prostatectomy bed in T2-weighted images; the pres-
ence of an area or hyperintense nodular lesion on the
diffusion map, and a hypointense lesion on the ADC map
with low ADC values and a DCE image showing an
intense, early enhancement with plateau (type 2 curve) or
posterior washing (type 3 curve). LR was positive con-
sidered when two or more sequences were abnormal.
LNR were considered pathological when the short axis
diameter was longer than 8 mm, the MRI signal was het-
erogeneous, and the contour was irregular. BM was con-
sidered pathological when abnormalities were evident on
T2 and DWI.
18F-CH PET/CT
18F-CH deposits with higher-than background activity
not explained by physiological phenomena were consid-
ered positive. Semi-quantitative analysis of the abnormal
radiotracer uptake was performed by using the max-
imum standardized uptake value (SUVmax). This value
was obtained automatically.
Salvage treatment
Patients who presented post-RP biochemical recurrence
without visible evidence of a tumor on the imaging tech-
niques were treated with rescue RT (70–74 Gy) to the
prostate bed. In patients with LR, the dose was increased
to 76 Gy. Patients with a pelvic LNR received RT to the
pelvic lymph nodes (52.8 Gy at 1.6 Gy/fraction) and the
prostatectomy bed (66 Gy at 2 Gy/fraction), together
with a simultaneous integrated boost (SIB) to affected
lymph nodes (72.6 Gy at 2.2 Gy/fraction). The pelvic
BMs were also included within the RT treatment volume
with SIB (72.6 Gy at 2.2 Gy/fraction). In patients who
had been previously treated with prostate bed RT and
later developed pelvic LNR and/or BM, stereotactic frac-
tionated body radiotherapy (SBRT) was prescribed to
this localization (excluding the pelvis) as follows: BM:
27–35 Gy in 3 or 5 fractions; LNR: 30–37.5 Gy in 3 or 5
fractions. In oligometastatic (<5 metastases) patients with
distant metastases, each lesion was treated with SBRT.
ADT was added to the RT prescription at the discretion
of the treating physician. However, patients with multiple
distant metastases were treated with ADT alone.
Statistical analysis
Quantitative variables are given as medians with inter-
quartile range (IQR) or as a mean ± standard deviation
(SD). For qualitative variables, absolute and relative fre-
quencies are given in percentages. The chi-square test
was used to analyze qualitative variables. The student’s T
test or the Mann–Whitney U Test were used, as appro-
priate, to analyze significant differences among the
quantitative variables.
McNemar’s test was used to analyze differences be-
tween mpMRI and 18F-CH PET/CT in detection rates.
A per patient analysis was performed. A Venn’s diagram
was used to show the distribution of LR and LNR [15].
A univariate/multivariate logistic regression analysis
was performed to identify independent variables associ-
ated with the imaging findings. The statistical analysis
was performed using SPSS, v. 21.0 (IBM Corp; Armonk,
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NY; USA), with p < 0.05 considered significant for all
analyses.
Results
The clinical characteristics and the variables related to
the treatment of the 38 patients included in this study
are detailed in Table 1. Treatment before 18F-CH PET/
CT and mpMRI imaging consisted of the following: in
27 patients (71.1%), RP alone; in 4 patients (10.5%), RP
plus ADT; and in 7 patients (18.4%), RP plus salvage RT.
The median time relapsed from RP to mpMRI and 18F-CH
PET/CT was 27.5 months [54]. Median age was 62.9 years
[7.2]. In 13 cases (34.2%), the tumour stage was pT3. The
Gleason score was >7 in 10 (26.3%) patients. Sixteen pa-
tients (42.1%) had positive surgical margins. The median
PSA value prior to imaging was 0.9 ng/mL (interquartile
range 0.4–2.2).
Separately, mpMRI and 18F-CH PET/CT were positive
for recurrence in 55.2% (21/38 patients) and 52.6% (20/
38 patients) of cases, respectively. When combined find-
ings were considered, 65.7% (25/38 patients) of cases
were positive for recurrence (Fig. 1). The combination of
MRI and choline PET/CT resulted in a higher detection
rate for LR versus choline PET/CT alone (34.2% vs
18.4%, p = 0.04). No significant differences were ob-
served between 18F-CH PET/CT imaging and mpMRI
imaging in terms of their detection rates for LR, LNR
and BM, which were, respectively, as follows: 18.4% vs
31.6% (p = 0.12), 31.6% vs 26.3% (p = 0.50), and 7.9% vs
10.5% (p = 1.00) (Table 2). Distance metastases were de-
tected by 18F-CH PET/CT in 5 patients (3 patients with
mediastinal lymph node metastases, 1 with a supraclavicu-
lar nodal metastasis, and 1 with retroperitoneal metastases).
Overall, the radiological findings of both tests disagreed in
10 cases.
The initially planned salvage treatment was modified
in 22 patients (57.8%) due to mpMRI and/or 18F-CH
PET/CT findings (Table 3).
Clinical variables associated with the radiological findings
The 21 patients with a positive mpMRI had significantly
higher PSA values prior to imaging than patients with a
negative mpMRI (Table 4). Patients with a positive
mpMRI had a significantly higher median PSA at bio-
chemical failure compared to patients with negative
mpMRI findings (0.9 [1.2] ng/mL versus 0.4 [0.1] ng/mL,
p = 0.005). PSA values were significantly associated with a
positive mpMRI (odds ratio [OR]: 30.9; 95% confidence
interval [CI]: 1.5–635.8) (Table 5).
The 20 patients with a positive 18F-CH PET/CT pre-
sented significantly higher PSA values prior to imaging
than patients with a negative PET/CT (Table 4). Addition-
ally, the Gleason score and subsequent PET/CT findings
were significantly associated: of the 10 patients with a
Gleason score >7, nine (90%) had a positive PET/CT;
however, of the 28 patients with a Gleason score ≤7, only
11 (39.3%) had a positive PET/CT. Consequently, Gleason
score > 7 was significantly associated with a positive PET/
CT (OR: 13.9; 95% CI: 1.5–125.6) (Table 5).
LR occurred in 13 patients. Additional file 1 shows the
distribution of clinical variables in this subgroup. On the
multivariate analysis, a significant association was found
between PSADT (OR: 1.3; 95% CI: 1.0–1.7), T stage (OR:




Age, years 62,9 ± 7,2








≤ 7 28 (73,7)











Post radical prostatectomy 0,1 [0,3]
On day of biochemical failure 0,4 [0,7]
On day of choline PET/CT and mpMRI 0,9 [1,8]
Lowest PSA level after surgery 0,1 [0.3]
Treatment before mpMRI/choline PET/CT
Radical prostatetcomy only 27 (71,1)
Radical prostatectomy and hormonotherapy 4 (10,5)
Radical prostatectomy and radiotherapy 7 (18,4)
Time from prostatectomy, months
To first PSA recurrence 10,5 [22,3]
To mpMRI/PET/CT 27,5 [54,0]
PSA doubling time, months 4,5 [8,3]
Mean ± standard deviation; Median [interquartile range]; n (%)
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21.1;95% CI:1.6–272.1), and the presence of LR
(Additional file 2).
A total of 12 patients presented LNR. In patients with
a Gleason score > 7, six of 10 patients (60%) developed a
LNR versus only six of the 28 patients (21.4%) with a
Gleason score ≤7, a significant difference (p = 0.04). PSA
values (first PSA after surgery, PSA at biochemical fail-
ure, and nadir PSA after RP) were all significantly higher
in patients who developed LNR. PSADT, the time
elapsed from RP to first biochemical recurrence, and
time elapsed from surgery to MRI and PET-CT, were all
significantly shorter in patients who developed LNR (see
Additional file 3). The univariate analysis showed a
significant association between Gleason score (OR: 5.5;
95% CI: 1.2–26.0), PSADT (OR: 0.74; 95% CI: 0.56–0.97)
and the presence of LNR (see Additional file 4). On the
multivariate analysis, no associations were observed be-
tween any of the clinical variables and LNR.
Discussion
To our knowledge, this is the first study to compare
3T-mpMRI without endorectal coil to 18F-CH PET/
CT to determine their relative capacity to detect pel-
vic tumor recurrences following RP. Although the de-
tection rate of LR, LNR and BM was similar in both
imaging techniques, the combination of mpMRI and
Fig. 1 Representative images of different pelvic tumor recurrences detected by mpMRI and 18F-CH PET/CT (arrows). a Local recurrence in axial
T2-weighted MRI and b local recurrence in 18F-CH PET/CT. c Right external iliac lymph node detected by axial T2-weighted MRI. d 18F-CH PET/CT
image at corresponding level demonstrates choline-avid right external iliac lymph node. e Axial Diffusion Weighted Imaging (DWI) of bone
metastases in left sacrum (arrow) and; f 18F-CH PET/CT shows a hypermetabolic bone metastases in right acetabulum
Table 2 Comparison of the detection rate of mpMRI versus 18F-Choline PET/TC versus Both tests in the diagnosis of tumor recurrences
in patients with biochemical relapse following radical prostactectomy. The right panel shows a Venn’s Diagram of the distribution of the
most frequent recurrences of these patients: LR and LNR
LR local recurrence, LNR lymph node recurrence, BM bone metastases
Statistically significant value, *p < 0.05 vs. Both test are in bold
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18F-CH PET/CT was superior to PET/CT alone in
the detection of LR.
Few studies have compared mpMRI to choline PET/
CT in the context of biochemical relapse after RP.
Kitajima et al. retrospectively compared 11C-choline PET/
CT to 1.5T and 3T mpMRI with endorectal coil to detect
pelvic recurrences after RP in 115 PCa patients [8]. In that
study, mpMR imaging with endorectal coil was superior
to PET/CT in the detection of LR, but PET/CT was su-
perior for detecting LNR; both were equally excellent for
pelvic BM []. Panebianco et al. compared 3T MRI with
endorectal coil to 18F-CH PET/CT in 84 patients with
PCa recurrence [7], finding a diagnostic accuracy of MRI
for LR higher than that of PET/CT.
In recent years, a new generation of targeted tracers for
PET imaging, primarily PSMA, has shown promising re-
sults, with a better detection rate than MRI or choline im-
aging, even in patients with low PSA levels (≤0.5 ng/mL)
[3]. However, we are still awaiting the results of validation
studies currently in progress [16].
We found that, the tumor detection rate in our patient
cohort was high: nearly two-thirds for combined MRI
and PET/CT versus approximately half for both MRI
and PET/CT alone. In addition, the combination of
the imaging techniques versus choline PET/CT alone
achieved a significantly higher detection rate for LR. It is
worth highlighting the increasing clinical and diagnostic
role of the integrated PET/MRI scanner, an advanced
technique that combines the anatomical and functional
information provided by MRI with the higher specificity
of PET [17]. This hybrid PET-MRI system has shown
promising results in terms of tumor detection compared
to MRI or PET alone [17]. For this reason, the high detec-
tion rate for MRI and choline PET/CT allows us to define
the site of recurrence, assess for metastatic disease, and
personalize salvage therapy. Thus, the use of combined
data in our study had an important impact on salvage RT
treatment decisions, leading us to change the therapeutic
approach in nearly 60% of cases.
Salvage RT is the primary treatment option in patients
who suffer a relapse after RP. Although the most
common approach is to irradiate the surgical bed (even
when there is no radiological or histological evidence of
disease), various questions remain unresolved with re-
gard to optimal target volume definition and RT doses
[16]. Of the 38 patients in our study, 13 (34.2%) devel-
oped LR. In 8 of these patients, we were able to escalate
the RT dose to 76 Gy at the recurrence site. This is im-
portant because the dose needed to achieve biochemical
control can vary depending on whether the recurrence is
micro- or macroscopic [18]. Moreover, when the im-
aging studies show no evidence of recurrence, radiation
oncologists define the prostate bed and clinical target
volume (CTV) blindly, based on recommendations pub-
lished in clinical guidelines [19]. However, in some cases,
following these guidelines can result in the tumor being
excluded from the CTV [20]. Similarly, the decision to
irradiate the prostate bed or the whole pelvis will depend
on the localization of the recurrence, which can be local
or loco-regional.
Although metastatic PCa has traditionally been treated
with ADT alone, the recent increase of metastases-
directed therapy in oligometastatic patients, has made it
even more important to accurate detect the presence of
LNR and BM after RP in order to properly manage these
patients [21]. In our study, oligometastatic lesions (bone
and/or lymph nodes) were detected outside of the pros-
tate bed in nearly 37% of patients. In these cases, the ini-
tial salvage RT plan to the prostate bed would have been
completely ineffective. For this reason, the definitive
treatment included metastases-directed therapy with RT
and ADT. Although it is true that the optimal therapy in
patients with nodal or pelvic bone involvement remains
unclear, a recent review of studies that assessed surgical
and RT treatment of oligometastatic PCa concluded
that, in general, both of these treatment approaches can
achieve good outcomes in terms of disease control and
increased survival, with only limited toxicity [21].
In terms of the association between clinical variables
and the findings of the imaging tests, several points are
worth highlighting. Patients with positive MRI and PET/
CT findings had PSA values that were significantly
Table 3 Modification of salvage treatment after radiological findings of mpMRI and/or 18F-CH PET/CT
N Initial treatment Salvage treatment, initially
planned BEFORE imaging
Radiological findings of mpMRI
and/or 18F-CH PET/CT
Salvage treatment, planned AFTER
imaging
8 Radical prostatectomy RT on prostate bed LR Boost on tumor bed
1 Radical prostatectomy RT on prostate bed Pelvic LNR + one pelvic BM RT on pelvis (including LNR and pelvic BM
with SIB) + ADT
1 Radical prostatectomy and ADT RT on prostate bed LR+ One pelvic BM RT on bed + BM + ADT
8 Radical prostatectomy RT on prostate bed Pelvic LNR RT on pelvis (including LNR with SIB) + ADT
1 Radical prostatectomy and adjuvant
radiotherapy
ADT Pelvic and retroperitoneal
LNR + one pelvic BM
SBRT on affected node and BM + ADT
3 Radical prostatectomy and ADT RT on prostate bed LR + Pelvic LNR RT on pelvis (including LR and LNR
with SIB) + ADT
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greater than those observed in patients with negative
findings on the imaging tests. In fact, although we only
found an association between PSA values at the time of
biochemical failure and MRI positivity, many studies
have reported an association between PSA and choline
PET/CT [22]. Thus, after RP, the optimal PSA cut-off
level for choline PET/CT analysis seems to be between 1
and 2 ng/mL [23], while for MRI, the corresponding
value appears to range from 0.3 to 0.54 ng/mL [5]. In
addition to the PSA value, several studies have reported
that PSA kinetics (PSADT, PSA velocity) are strong pre-
dictors for positive PET and MRI findings, even in pa-
tients with low PSA values [4, 5, 23]. We found that
PSADT was significantly associated with the type of pel-
vic recurrence: patients with a higher PSADT had an in-
creased probability of local recurrence. Hernández et al.
demonstrated a significantly shorter PSADT in patients
with LNR [5]. In the other hand, the Gleason score
should be considered when evaluating the utility of 18F-
CH PET/CT as it has been related to the PET/CT











Age, years 63,2 ± 7,2 62,5 ± 7,4 0,767 63,4 ± 7,6 62,4 ± 6,8 0,703
Preoperative PSA, ng/mL 7,7 [14,0] 7,0 [8,4] 0,453 7,4 [9,1] 7,5 [12,1] 0,65
Pathologic T stage (%)
T2 11 (44,0) 14 (56,0) 0,086 11 (44,0) 14 (56,0) 0,182
T3 10 (76,9) 3 (23,1) 9 (69,2) 4 (30,8)
Pathologic N stage, n (%)
N0 9 (56,3) 7 (43,8) 0,917 10 (62,5) 6 (37,5) 0,299
Nx 12 (54,5) 10 (45,5) 10 (45,5) 12 (54,5)
Pathologic Gleason score, n (%)
≤ 7 13 (46,4) 15 (53,6) 0,136 11 (39,3) 17 (60,7) 0,009
> 7 8 (80,0) 2 (20,0) 9 (90,0) 1 (10,0)
Positive surgical margin, n (%)
Yes 8 (50,0) 8 (50,0) 0,578 6 (37,5) 10 (62,5) 0,111
No 13 (59,1) 9 (40,9) 14 (63,6) 8 (36,4)
Perineural Invasion, n (%)
Yes 10 (58,8) 7 (41,2) 0,691 9 (52,9) 8 (47,1) 0,973
No 11 (52,4) 10 (47,6) 11 (52,4) 10 (47,6)
Lymphatic vessel invasion, n (%)
Yes 2 (50,0) 2 (50,0) 1,000 2 (50,0) 2 (50,0) 1,000
No 19 (55,9) 15 (44,1) 18 (52,9) 16 (47,1)
PSA levels, ng/mL
Post radical prostatectomy 0,2 [1,4] 0,0 [0,1] 0,006 0,2 [1,3] 0,0 [0,1] 0,007
On day of biochemical failure 0,9 [1,2] 0,4 [0,1] 0,005 0,7 [1,1] 0,4 [0,1] 0,009
On day of CH PET/CT and mpMRI 2,0 [1,9] 0,4 [1,0] 0,024 2,0 [1,7] 0,4 [0,7] 0,019
Lowest PSA level after surgery 0,2 [1,4] 0,0 [0,1] 0,012 0,2 [1,2] 0,0 [0,1] 0,003
Treatment before mpMRI/18F-CH PET, n (%)
Radical prostatectomy only 14 (51,9) 13 (48,1) 0,508 15 (55,6) 12 (44,4) 0,572
Prostatectomy and HT or RT 7 (63,6) 4 (36,4) 5 (45,5) 6 (54,5)
Time from prostatectomy, months
To first PSA recurrence 5,0 [36,0] 16,0 [18,5] 0,075 5,5 [21,0] 16,5 [25,0] 0,079
To mpMRI/PET/CT 31,0 [55,5] 27,0 [44,5] 0,596 10,5 [36,0] 32,0 [48,0] 0,187
PSA doubling time, months 4,0 [9,5] 5,8 [8,5] 0,634 3,1 [5,3] 8,5 [9,5] 0,135
Mean ± standard deviation; Median [interquartile range]
Statistically significant value, p < 0.05 are in bold
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positivity [24]. T staging was also significantly associated
with LR: patients with extracapsular involvement (T3)
had an increased probability of developing LR, a finding
that is congruent with the beneficial effect of adjuvant
RT in the patient subgroup with extracapsular invasion
or seminal vesicle involvement [23]. In short, all of these
variables should be taken into account when re-staging
patients who develop biochemical recurrence after RP in
order to select the most appropriate salvage therapy.
Our study has several limitations. First, this was a
retrospective analysis with a small sample size. Second,
there was some patient selection bias, as evidenced by
the fact that most patients who underwent mpMRI and
18F-CH PET/CT had positive radiological findings. This
can be attributed to various factors, as follows: pre-
imaging PSA values were relatively high in the entire co-
hort, the time to biochemical failure was short, and the
PSADT values low. All of these clinical characteristics
are indicative of highly aggressive disease with a high
probability of tumor recurrence that are detectable on
both imaging tests. Third, the specific choline PET/CT
protocol and the radiotracer used in this study could
have influenced the quality of the images and thus their
interpretation. However, a recent metanalysis concluded
that (11) C-choline and 18F-CH and the different acqui-
sition protocols had no significant impact on the detec-
tion rate [25]. Fourth, the MRI and PET images were
acquired in separate imaging sessions and this may have
affected the detection rate compared to the hybrid PET-
MRI system, as mentioned before. Fifth, we did not use
endorectal coil and this may have influenced the reliabil-
ity of the MRI images [26]. Nevertheless, in patients with
tumor recurrence after RP, the tumor detection rate
using a 3T MRI seems not to be influenced by the type
of coil [4]. Lastly, in our study 4 patients received ADT
before MRI and PET/CT, which could have a limited up-
take on the choline PET/CT and caused morphological
changes and alterations in the parameters of the DWI
and DCE on the MRI [27, 28]. However, data from our
study and others [7] show that this does not directly in-
fluence the comparative analysis. In fact, in three of
these four patients the recurrence was identified by both
imaging techniques.
The strength of the study is the blinded evaluation of
all images at the same institution by two different ex-
perts (an uro-radiologist and a nuclear medicine special-
ist). In addition, this is the first study to compare 3T
mpMRI without endorectal coil to 18F-CH PET/CT in
this context.
Conclusion
Multiparametric MRI and 18F-CH PET/CT yield similar
detection rates for LR, LNR and pelvic BM. The com-
bination of both imaging techniques provides a better
Table 5 Univariate analysis of the clinic characteristics associated to the positivity of mpMRI and 18F-CH PET/CT
mpMRI 18F-CH PET/CT
OR (95% CI) p value OR (95% CI) p value
Age, years 1.01 (0.93–1.10) 0.759 1.02 (0.93–1.12) 0.694
Preoperative PSA, ng/mL 1.05 (0.95–1.15) 0.344 0.98 (0.89–1.07) 0.630
Pathologic T stage, T3 4.24 (0.94–19.26) 0.061 2.86 (0.69–11.82) 0.146
Pathologic N stage, Nx 0.93 (0.26–3.41) 0.917 0.50 (0.13–1.86) 0.301
Pathologic Gleason score, > 7 4.62 (0.83–25.73) 0.081 13.91 (1.54–125.63) 0.019
Positive surgical margin 0.69 (0.19–2.53) 0.578 0.34 (0.09–1.30) 0.116
Perineural Invasion 1.30 (0.36–4.72) 0.691 1.02 (0.28–3.68) 0.973
PSA levels, ng/mL
Post radical prostatectomy 20.66 (0.45–964.07 0.121 2.17 (0.71–6.63) 0.172
On day of biochemical failure 30.90 (1.50–635.84) 0.026 2.48 (0.76–8.15) 0.135
On day of MRI-PET/CT 1.62 (0.88–2.98) 0.122 1.64 (0.90–2.99) 0.110
Lowest PSA level after surgery 16.77 (0.530–531.40) 0.110 2.03 (0.72–5.69) 0.180
Treatment before mpMRI/choline PET/CT
Radical prostatectomy and hormonotherapy or radiotherapy 1.63 (0.38–6.87) 0.509 0.67 (0.16–2.73) 0.573
Time from prostatectomy
To first PSA recurrence 0.99 (0.95–1.03) 0.568 0.98 (0.94–1.01) 0.217
To MRI-PET/CT 1.00 (0.98–1.02) 0.807 0.99 (0.97–1.01) 0.203
PSA doubling time, months 1.02 (0.92–1.12) 0.772 0.94 (0.85–1.05) 0.271
Statistically significant value, p < 0.05 are in bold
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LR detection rate after RP versus choline PET/CT alone.
The initially planned salvage treatment was modified in
57.8% of patients due to both imaging techniques find-
ings. In addition to PSA values, Gleason score, T stage,
and PSADT may provide valuable data to identify those
patients that are most likely to benefit from undergoing
both imaging procedures.
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